文献速递淋巴瘤白血病

CD19靶向嵌合抗原受体修饰T细胞免疫治疗的感染并发症

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
PubMed 文献 · Blood · 2017-10-16

本文在1/2期研究中评估133例接受CD19 CAR-T细胞治疗的复发或难治性B细胞恶性肿瘤患者第0至90天的感染情况,采用泊松回归与Cox回归分析治疗前后感染危险因素;结果显示CAR-T输注后28天内感染密度为每100个风险日1.19次,第29至90天降至0.67(P=.02)。

要点

  • 133例中30例(23%)在输注后28天内发生43次感染,首次感染中位时间为输注后6天。
  • 6例(5%)发生侵袭性真菌感染,5例(4%)发生危及生命或致命性感染。
  • 多变量分析中,细胞因子释放综合征(CRS)严重度是CAR-T输注后唯一与感染相关的因素。

核心结论

  • CD19 CAR-T细胞治疗的感染发生率与类似患者挽救性化学免疫治疗临床试验的观察结果相当。
  • CAR-T输注后多变量分析中,CRS严重度是唯一与感染相关的因素。

研究设计与样本

  • 1/2期研究,纳入133例接受CD19 CAR-T细胞治疗的复发或难治性B细胞恶性肿瘤患者,评估第0至90天的感染。
  • 队列包括急性淋巴细胞白血病(ALL)47例、慢性淋巴细胞白血病24例、非霍奇金淋巴瘤62例。
  • 采用泊松回归和Cox回归分别评估治疗前和治疗后感染危险因素。

主要发现

  • 133例中30例(23%)在CAR-T输注后28天内发生43次感染,感染密度为每100个风险日1.19次。
  • 第29至90天感染密度较低,为0.67(P=.02)。
  • 首次感染发生于CAR-T输注后中位6天。
  • 6例(5%)发生侵袭性真菌感染,5例(4%)发生危及生命或致命性感染。
  • 在基线特征校正模型中,ALL、既往≥4种抗肿瘤方案及接受最高CAR-T细胞剂量(2×10^7个细胞/kg)者28天内感染密度更高。

关键数值与推荐

  • CAR-T输注后28天内感染密度为每100个风险日1.19次,第29至90天为0.67(P=.02)。
  • 最高CAR-T细胞剂量为2×10^7个细胞/kg。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lymphodepletion chemotherapy with CD19-targeted chimeric antigen receptor-modified T (CAR-T)-cell immunotherapy is a novel treatment for refractory or relapsed B-cell malignancies. Infectious complications of this approach have not been systematically studied. We evaluated infections occurring between days 0 to 90 in 133 patients treated with CD19 CAR-T cells in a phase 1/2 study. We used Poisson and Cox regression to evaluate pre- and posttreatment risk factors for infection, respectively. The cohort included patients with acute lymphoblastic leukemia (ALL; n = 47), chronic lymphocytic leukemia (n = 24), and non-Hodgkin lymphoma (n = 62). There were 43 infections in 30 of 133 patients (23%) within 28 days after CAR-T-cell infusion with an infection density of 1.19 infections for every 100 days at risk. There was a lower infection density of 0.67 between days 29 and 90 (P = .02). The first infection occurred a median of 6 days after CAR-T-cell infusion. Six patients (5%) developed invasive fungal infections and 5 patients (4%) had life-threatening or fatal infections. Patients with ALL, ≥4 prior antitumor regimens, and receipt of the highest CAR-T-cell dose (2 × 107 cells per kg) had a higher infection density within 28 days in an adjusted model of baseline characteristics. Cytokine release syndrome (CRS) severity was the only factor after CAR-T-cell infusion associated with infection in a multivariable analysis. The incidence of infections was comparable to observations from clinical trials of salvage chemoimmunotherapies in similar patients. This trial was registered at www.clinicaltrials.gov as #NCT01865617.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2017. PMID: 29038338. doi:10.1182/blood-2017-07-793760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。